Skip Navigation
Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

HIV/AIDS Active Grants

(under RFAs and PAs only)

For information on any of the grants listed below, please use the National Institutes of Health (NIH) Research Portfolio Online Reporting Tools Expenditures and Results (RePORTER) system. RePORTER is an electronic tool that allows users to search for information on NIH-funded research projects.

Targeting Persistent HIV Reservoirs (TaPHIR) (PAR-12-109):

  • Persistent virus reservoirs in SIV-infected macaques, Mirko Paiardini
  • Targeting the persistent HIV-1 viral reservoir using engineered T cells, James Riley
  • Synthetic molecular sensors to target latently infected cells for HIV eradication, Christopher Woelk
  • Specific Killing of latently HIV-1-infected cells after provirus reactivation, Qigui Yu
  • A micro-co-culture assay for single-cell analysis of HIV Latency, Matthew Strain
  • HIV eradication by ADCC-activated NK cell killing, Jonathan Karn
  • Novel flow cytometry-based assay for HIV-infected cells, Joseph M. McCune
  • Targeting HIV Lung Reservoir in the Macaque Model, Marcelo Kuroda
  • Specific activation of latent HIV-1 by inhibiting E3 ubiquitin ligase activity, Joseph Dougherty
  • Killing the Reservoir with Antibodies, Galit Alter
  • Inhibiting Immune Evasion by HIV-1 Nef to Facilitate Eradication, John Guatelli
  • Cell-Based Secretion of Antiviral Molecules as a Treatment for HIV-AIDS, Hans-Peter Kiem
  • HIV-specific nucleases to reservoir cells, Paula Cannon
  • A family of compounds that reactivate latent HIV without T cell activation, Alberto Bosque
  • Modified CMV-specific T cells to Target HIV, Stephen Braun
  • Characterization of follicular dendritic cells as a reservoir for HIV, Michael Carroll
  • Lineage marking in humanized mice to reveal HIV-1 reservoirs, Benjamin Chen
  • Development of Nef antagonists to enhance CTL clearance of HIV reservoirs, Kathleen Collins
  • Novel small molecules to reactivate latent HIV and sensitize to anti-viral therapies, Ivan D’Orso and Elisabeth Martinez
  • Effective lethal agents for CCR5 expressing cells, Dennis Hartigan-O’Connor
  • Targeting latent HIV-1 Reservoirs with the Antibody-Drug Conjugate Brentuximab Vedotin, Timothy Henrich
  • Curing HIV Through Allogeneic Hematopoietic Stem Cell Transplantation, Leslie Kean
  • Targeting Macrophage Reservoirs in the Macaque Model of Pediatric AIDS, Marcelo Kuroda
  • Kinomic analysis of host cell factors controlling latent HIV-1 infection, Olaf Kutsch
  • Targeting Cytolytic Cells to Lymphoid Sites of HIV Persistence, Michael Lederman and Mirko Paiardini
  • Adipose Tissue is a significant reservoir for HIV, Dorothy Lewis and Ashok Balasubramanyam
  • An ex vivo model to predict outcomes and probe mechanism of anti-reservoir agents, Una O’Doherty
  • Role of P-TEFB in HIV latency, Andrew Rice
  • Alpha Emitter Labeled Anti-T Cell Antibody: Targeting Latent HIV Infected Cells, Brenda Sandmaier
  • Targeting SIV reservoirs with type I Interferons, Guido Silvestri
  • High throughput analysis of latency/reactivation with barcoded proviruses, Alice Telesnitsky, Cheong-Hee Chang, and Jeffrey Kidd
  • Purging the latent HIV reservoir at ART initiation: A new eradication strategy, Lydie Trautmann and Nicolas Chomont
  • Suppressing the latent reservoir with a Tat inhibitor, Susana Valente
  • Therapeutic vaccination targeting SIV viral reservoirs, Vaiva Vezys
  • Evaluating HIV expression and latency in blood and tissues at the single cell level, Joseph Wong
  • Targeting HIV-1 persistence with Interferon-alpha, Xu Yu
  • Cooperation of BRD4 and TAT Associated Proteins in HIV Transcription and Latency, Jian Zhu

Innovative Assays to Quantify the Latent HIV Reservoir (RFA-AI-13-038)

  • TILDA: A new sensitive and precise assay to measure the size of the latent HIV reservoir, Nicolas Chomont
  • A Novel Microfluidic HIV-1 Co-Culture Assay to Quantify Latent Reservoirs, Timothy Henrich
  • Nanotrap particle-based assay to quantify HIV-1 in latently-infected T cells, Fatah Kashanchi
  • New and Simple Assay to Measure Latent HIV Reservoir Using Deep Sequencing Method, Sook-Kyung Lee
  • Simplified Assays of Latent But Inducible HIV-1 Reservoirs, John Mellors
  • Novel methods for measuring the reservoir of inducible HIV-1 proviruses in resting CD4+ T cells, Janet Siliciano
  • Detection of Latent HIV Infection Using Selective Reaction Monitoring Mass Spectrometry, John Tilton

Innovative Assays to Quantify the Latent HIV Reservoir (RFA-AI-14-020)

  • An Ultrasensitive In Vivo Latent HIV Viral Outgrowth Assay Using Humanized Mice, Ramesh Akkina
  • A mouse viral outgrowth assay for the detection of residual HIV-1 reservoirs, Joel Blankson
  • A FAST Assay to Quantify HIV Reservoirs, Una O’Doherty and Lidia Sambucetti
  • High-throughput Deep Sequencing Assay to Reliably Measure the HIV Reservoir during Antiretroviral Therapy, David Mitchell Smith

Basic Research on HIV Persistence (PA-12-161 and PA-12-162)

  • Phenotypic Analysis of Latently Infected CD4+ T Cells, Joel Blankson
  • Gene Engineering Using CRISPR/Cas9 Mutagenesis to Eliminate Latent HIV-1, Irvin Chen
  • HIV Infection in Bone Marrow: A Reservoir for Viral Persistence, Suzanne Gartner
  • Novel Compounds That Target HIV Latency, Andrew Henderson
  • Microfluidic PCR Method to Identify and Characterize HIV-Infected Single Cells, Timothy Henrich and Utkan Demirci
  • Quantifying the Effect of HIV Latency, Thomas Leitner
  • HIV Cure With CCr5 (-) Human IPS Hematopoietic Stem Cells, Jay Levy
  • Predictors of HIV Control after Antiretroviral Treatment Interruption, Jonathan Li
  • Effects of Acitretin on the Activation of Latent HIV, Peilin Li
  • Limiting HIV-1 Persistence by Targeting Stem Cell Properties of CD4 T Cells, Mathias Lichterfeld
  • The Role of Gamma Delta T Cells as Persistent Reservoirs of HIV Infection, David Margolis
  • Novel Mechanisms for Coreceptor Switching, Donald Mosier
  • Probing Mechanisms of Reduced HIV Reservoirs in an Interferon-alpha Clinical Trial, Una O’Doherty
  • Central Memory CD4 T Cell Infection: Key Role in ART Response and HIV Persistence, Mirko Paiardini and Vincent Marconi
  • Genetic Analysis of Unspliced HIV RNA Produced During HDAC Inhibitor Therapy, Sarah Palmer
  • Assessing Potential Latent Virus HIV-1 Viability Using Next Generation Sequencing, Christos Petropoulos
  • Quantitative Viral Outgrowth Assays With Improved Throughput and Performance, Christos Petropoulos
  • Characterization of the HIV-1 Latent Reservoir in CCR5-Delta 32 Heterozygotes, Satish Pillai
  • Mechanisms of Reactivation of Latent HIV by HDAC Inhibitors, Andrew Rice
  • Cell Surface Marker Combinations to Identify Latently Infected CD4+ Cells In Vivo, Fabio Romerio
  • Persistence and Fate of Invisible U/A Pairs in HIV-1 Proviral DNA, James Stivers
  • Heat Shock Protein 90 and HIV Persistence, Cheryl Stoddart
  • HIV-1 Reservoir Dynamics in the Female Genital Tract, Athe Tsibris
  • T Follicular Regulatory Cells, a Potential HIV Reservoir, Christel Uittenbogaart
  • Elimination of Persistently HIV-Infected Cells by Targeting Host Factors, Mark Wallet
  • Epigenetic Regulation of T-cell Exhaustion During Treated Chronic HIV Infection, Benjamin Youngblood
  • HIV 2-LTR Dynamics and Cryptic Viremia, Ryan Zurakowski

Basic Research on HIV Persistence (PAR-14-247 and PAR-14-248)

  • Kupffer Cells and HIV-1 Persistence, Ashwin Balagopal
  • Viral and Immune Dynamics of Rebound Viremia after VRC01 Administration, Katharine Bar
  • Viral control mechanisms of HIV-specific T cells in HIV-infected lymph node, Michael Betts
  • Reservoir depletion and anti-retroviral therapy for infant functional cure, Dennis Hartigan-O’Connor
  • High-throughput measurement and transcriptome analysis of the latent reservoir using HIV-1 RNA flow-FISH, Ya-Chi Ho
  • The contribution of unintegrated HIV-1 to latency and to models of latency, David Levy
  • Timing of ART and homeostasis of the persistent HIV reservoir in the adult, Joseph M. McCune
  • Immune based interventions for HIV eradication, Mirko Paiardini
  • Cholesterol-dependent control of HIV progression by antigen presenting cells, Charles Rinaldo and Giovanna Rappocciolo
  • Towards HIV eradication using a novel Tat inhibitor, Susana Valente
  • Bacterial toxin-inspired drug delivery (BTIDD) platforms against latent HIV, Brenda Wilson

Martin Delaney Collaboratory: Towards an HIV Cure (RFA-AI-10-009)

  • Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection, Keith Jerome and Hans-Peter Kiem
  • Martin Delaney Collaboratory to Eradicate HIV-1 Infection, David Margolis
  • DARE: Delaney AIDS Research Enterprise to Find a Cure; Steven Deeks, J. Michael McCune, and Rafick Sekaly

For current information on collaboratory research, visit the following websites:

Beyond HAART: Innovative Therapies to Control HIV-1 (RFA-AI-11-012)

  • A Gene Therapeutic Approach to Stable Suppression of HIV-1 Replication, Michael Farzan
  • RNA directed silencing and excision of HIV-1 and CCR5, Kevin Morris

Beyond HAART: Innovative Approaches to Cure HIV-1 (RFA-14-004)

  • Anti-HIV Gene Therapy: Defend and Attack, Irvin Chen (NIAID)
  • Engineering T cells to Provide Durable Control of HIV-1 Replication, James Riley (NIAID)
  • Next Generation HSC Gene Therapy for HIV Control and Eradication, Paula Cannon and Hans-Peter Kiem (NHLBI)
  • A defend and destroy approach to curing HIV, David Scadden (NHLBI)

Delivering Therapeutics to Residual Active HIV Reservoirs (RFA-AI-12-042)

  • Plug and Purge: In Vivo Targeting of Active HIV Reservoirs That Persist Despite ART, Victor Garcia-Martinez
  • T-cell-mediated targeting of therapeutics to HIV reservoirs, Darrell Irvine and Bruce Walker
  • Multi-Species Mechanisms of Drug Bio-distribution in HIV Tissue Reservoirs, Angela Kashuba
  • Mechanisms of Formation and Persistence of Active HIV Reservoirs, James Mullins
  • Targeted inhibition of HIV-1 latency, Kevin Morris
  • Monitoring SIV reservoirs with whole body immunoPET, Francois Villinger and Philip Santangelo

Ethical Issues in Research in HIV/AIDS and its Co-morbidities (PAR-12-244)

  • HIV cure studies: risk, risk perception, and ethics, Nir Eyal
  • Advancing HIV Research in Pregnancy; ethics and engagement, Anne Lyerly
  • Assessing Social Justice in Economic Evaluation to Scale up Novel MDR-TB Regimens, Maria Merritt
  • Unintended and Intended Implications of HIV Cure: A Social and Ethical Analysis, Joseph Tucker

Last Updated July 14, 2015